DFDA

Concurrent Chemoradiation

Treatment for Esophageal Cancer

Typical Dosage: Chemotherapy: e.g., Cisplatin 75 mg/m2 D1, 5-FU 1000 mg/m2/day D1-4 (every 3 weeks for 2-3 cycles) OR Carboplatin AUC 2 + Paclitaxel 50 mg/m2 weekly. Radiation: 50.4 Gy in 28 fractions.

Effectiveness
85%
Safety Score
25%
Clinical Trials
196
Participants
30K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Chemotherapy: e.g., Cisplatin 75 mg/m2 D1, 5-FU 1000 mg/m2/day D1-4 (every 3 weeks for 2-3 cycles) OR Carboplatin AUC 2 + Paclitaxel 50 mg/m2 weekly. Radiation: 50.4 Gy in 28 fractions.
Time to Effect
1-2 months
Treatment Duration
5-6 weeks
Evidence Quality
HIGH
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$50,000
Side Effect Mgmt:$15,000
Total Annual:$80,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$114,285.71
Cost per Remission
$266,666.67
Concurrent Chemoradiation Outcomes

for Esophageal Cancer

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Remission Rate
+30%
Common Side Effects
Acute Esophagitis
+60%
Dysphagia
+40%
Nausea/Vomiting
+50%
Fatigue
+70%
Myelosuppression (Neutropenia)
+35%
Radiation Pneumonitis
+10%
Stricture
+20%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
6 active trials recruiting for Concurrent Chemoradiation in Esophageal Cancer

Adaptive Neoadjuvant Therapy for Esophageal Cancer

NCT06990178ENROLLING BY INVITATIONNA
View Study
43 participants
INTERVENTIONAL
Shenzhen, China
Started: Mar 1, 2028

Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer

NCT02972372RECRUITINGNA
View Study
196 participants
INTERVENTIONAL
Anyang, China +1 more
Started: Nov 1, 2016

Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.

NCT06452602NOT YET RECRUITINGPHASE2
View Study
60 participants
INTERVENTIONAL
Tianjin, China
Started: Jun 6, 2024

Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma

NCT04135664RECRUITINGPHASE3
View Study
176 participants
INTERVENTIONAL
Nanchang, China +5 more
Started: Sep 1, 2019

Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

NCT06354218RECRUITINGPHASE2
View Study
50 participants
INTERVENTIONAL
Nanjing, China
Started: Dec 1, 2023

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

NCT06430658RECRUITINGPHASE2
View Study
90 participants
INTERVENTIONAL
Beijing, China
Started: Apr 1, 2024
Completed Clinical Trials
4 completed trials for Concurrent Chemoradiation in Esophageal Cancer

Radiation Dose Escalation in Esophageal Cancer

NCT03082586COMPLETEDNA
View Study
31 participants
INTERVENTIONAL
Shanghai, China
Started: Nov 20, 2016

PET/CT-directed Hyperfractionated Radiation Dose Escalation in Esophageal Cancer

NCT03113214COMPLETEDNA
View Study
27 participants
INTERVENTIONAL
Shanghai, China
Started: Feb 2, 2017

Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer

NCT01691625COMPLETEDNA
View Study
50 participants
INTERVENTIONAL
Beijing, China
Started: Sep 1, 2012

Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

NCT06048913COMPLETEDPHASE2
View Study
56 participants
INTERVENTIONAL
Nanjing, China
Started: Dec 1, 2020
Showing 20 of 202 total trials